HC Wainwright Has Optimistic Outlook of Harrow Q3 Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Harrow, Inc. to $0.10, significantly up from the previous estimate of $0.02, while maintaining a "Buy" rating and a price target of $64.00.
• Harrow's stock has seen a recent price increase of 9.6%, currently trading at $40.01, following a quarterly earnings report that exceeded expectations with $0.24 EPS against a consensus estimate of $0.01.
• Institutional investors and hedge funds own 72.76% of Harrow's shares, indicating strong interest from large investors in the company’s growth potential.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Harrow in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $0.10 per share for the quarter, up from their prior forecast of $0.02. HC Wainwright has a "Buy" rating and a $64.00 price target on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow's Q4 2025 earnings at $0.25 EPS and FY2026 earnings at $0.93 EPS.

HROW has been the topic of a number of other research reports. Cantor Fitzgerald started coverage on shares of Harrow in a report on Friday, July 11th. They issued an "overweight" rating and a $76.00 price target on the stock. William Blair began coverage on shares of Harrow in a report on Tuesday, June 10th. They issued an "outperform" rating on the stock. BTIG Research upped their target price on shares of Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Finally, Zacks Research upgraded shares of Harrow from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to MarketBeat.com, Harrow has an average rating of "Buy" and an average price target of $64.67.

Harrow Stock Performance

Shares of NASDAQ HROW traded down $0.2220 during midday trading on Friday, reaching $38.0080. The company's stock had a trading volume of 296,469 shares, compared to its average volume of 482,431. Harrow has a 12-month low of $20.85 and a 12-month high of $59.23. The firm has a 50 day moving average price of $33.48 and a 200-day moving average price of $28.98. The stock has a market capitalization of $1.41 billion, a P/E ratio of -151.37 and a beta of 0.41. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. The business had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Harrow

Several large investors have recently made changes to their positions in the business. Teacher Retirement System of Texas increased its position in shares of Harrow by 4.1% during the second quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company's stock valued at $259,000 after acquiring an additional 332 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Harrow by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company's stock worth $505,000 after buying an additional 341 shares during the last quarter. Pale Fire Capital SE boosted its stake in shares of Harrow by 6.8% in the 2nd quarter. Pale Fire Capital SE now owns 8,683 shares of the company's stock worth $265,000 after buying an additional 550 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Harrow by 3.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company's stock worth $582,000 after acquiring an additional 585 shares during the period. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Harrow in the fourth quarter worth $25,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.